This study will test an experimental drug named TCMCB07 for the treatment of cancer cachexia. Cachexia is a syndrome characterized by weight loss, anorexia, weakness or lack of energy, and anemia. Cachexia occurs in many cancers, usually at the advanced stages of disease.

Inclusion Criteria:

• Healthy males and females (WONCBP), aged 18 to 55 years inclusive, at time of signing informed consent.
• Body mass index 18.0 to 30.0 kg/m2 as measured at Screening or, if outside this range, considered not clinically significant by the investigator.
• Weight ≥ 50 kg at Screening

Exclusion Criteria:

• Serious adverse reaction or serious known hypersensitivity to melanocortins or polyethylene glycol.
• Evidence of current severe acute respiratory syndrome coronavirus 2 infection.
• Clinically significant abnormal clinical chemistry, hematology, or urinalysis as judged by the investigator.
• Subjects who have received any IP in a clinical research study within 5 half-lives or within 30 days prior to first dose. However, in no event shall the time between last receipt of IP and first dose be less than 30 days.